Perspective Therapeutics (CATX) said Friday it has dosed the first patient in a new cohort of its phase 1/2a trial evaluating [212Pb]VMT01 as a monotherapy for melanoma patients with confirmed positive MC1R imaging scans.
This cohort includes patients with brain metastases and administers [212Pb]VMT01 at a dose of 1.5 millicuries.
The investigational therapy delivers targeted alpha-particle therapy to treat metastatic melanoma. The US Food and Drug Administration granted Fast Track Designation for [212Pb]VMT01 in September 2024.
Perspective Therapeutics shares were up over 17% in recent premarket activity.
Price: 2.19, Change: +0.33, Percent Change: +17.74
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。